Stockscreener 앱 받기
10.00
0.89%
-0.09
시간 외 거래:
10.00
전일 마감가:
$10.09
열려 있는:
$10.02
하루 거래량:
1.51M
Relative Volume:
0.94
시가총액:
$3.14B
수익:
$2.68B
순이익/손실:
$-184.45M
주가수익비율:
-14.70
EPS:
-0.6805
순현금흐름:
$229.23M
1주 성능:
+3.95%
1개월 성능:
+10.86%
6개월 성능:
+12.61%
1년 성능:
+18.06%
1일 변동 폭
$9.91
$10.11
1주일 범위
$9.585
$10.34
52주 변동 폭
$6.685
$10.34
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
명칭
Amneal Pharmaceuticals Inc
전화
908-947-3120
주소
400 Crossing Boulevard, 3rd Floor, Bridgewater
AMRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
10.00 | 3.08B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
148.20 | 66.22B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.10 | 48.29B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.81 | 43.99B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.93 | 22.45B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
405.02 | 17.93B | 2.99B | 1.21B | 1.13B | 25.06 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-06 | 개시 | Goldman | Buy |
| 2025-02-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-09-06 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | 업그레이드 | Goldman | Sell → Buy |
| 2020-12-14 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-12-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-07-27 | 개시 | Goldman | Sell |
| 2020-05-12 | 업그레이드 | Guggenheim | Sell → Neutral |
| 2019-12-12 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-07 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | 개시 | Barclays | Equal Weight |
| 2019-05-21 | 업그레이드 | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2019-03-08 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | 다운그레이드 | SunTrust | Buy → Hold |
| 2018-08-13 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | 개시 | Morgan Stanley | Overweight |
| 2018-06-22 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
Amneal Pharmaceuticals Inc 주식(AMRX)의 최신 뉴스
Amneal receives FDA approval of treatment for narcoleptic sufferers - ROI-NJ
Ophthalmic Packaging Market Worth USD 23.65 Billion by 2034 | Towards Packaging - GlobeNewswire Inc.
AMNEAL PHARMACEUTICALS (NASDAQ:AMRX) Hits New 1-Year HighWhat's Next? - MarketBeat
Ieq Capital LLC Takes $288,000 Position in AMNEAL PHARMACEUTICALS, INC. $AMRX - MarketBeat
Why Amneal (AMRX) Stock Is Up Today - Yahoo Finance
Amneal wins FDA nod for generic targeting Jazz Pharma’s Xyrem - Seeking Alpha
Amneal Pharmaceuticals Wins US FDA Approval for Generic Version of Narcolepsy Drug Xyrem - MarketScreener
Amneal receives US FDA approval of Sodium Oxybate Oral Solution - MarketScreener
Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution - GlobeNewswire
150,000 Narcolepsy Patients Get New Option: Amneal's FDA-Approved Generic Breaks Single-Maker Market - Stock Titan
Amneal Pharmaceuticals: A Large, Diversified Clinical Portfolio That Keeps Growing (AMRX) - Seeking Alpha
Amneal Pharmaceuticals, Inc. $AMRX Shares Bought by Raymond James Financial Inc. - MarketBeat
Northern Trust Corp Reduces Position in AMNEAL PHARMACEUTICALS, INC. $AMRX - MarketBeat
684,116 Shares in AMNEAL PHARMACEUTICALS, INC. $AMRX Bought by Cubist Systematic Strategies LLC - MarketBeat
Anti-Parkinson's Drugs Global Markets to 2030 with AbbVie, Amneal Pharmaceuticals, Acadia Pharmaceut - PharmiWeb.com
Anti-Parkinson's Drugs Global Markets to 2030 with AbbVie, Amneal Pharmaceuticals, Acadia Pharmaceuticals, Supernus Pharmaceuticals and Teva Pharmaceutical DominatingResearchAndMarkets.com - Business Wire
Amneal Pharmaceuticals stock hits 52-week high at $9.79 - Investing.com
Amneal Pharmaceuticals stock hits 52-week high at $9.79 By Investing.com - Investing.com Australia
Is Amneal Pharmaceuticals Inc. a strong growth stockJuly 2025 Analyst Calls & Community Shared Stock Ideas - beatles.ru
AMNEAL PHARMACEUTICALS, INC. $AMRX Shares Bought by Dark Forest Capital Management LP - MarketBeat
Is Amneal Pharmaceuticals Inc.’s ROE strong enough2025 Analyst Calls & Free Real-Time Volume Trigger Notifications - beatles.ru
Should you wait for a breakout in Amneal Pharmaceuticals Inc.Bear Alert & Fast Moving Stock Trade Plans - Newser
Can machine learning forecast Amneal Pharmaceuticals Inc. recoveryPortfolio Value Summary & Stock Portfolio Risk Management - Newser
Amneal Pharmaceuticals, Inc. $AMRX Shares Bought by Nantahala Capital Management LLC - MarketBeat
FDA Warns Amneal Pharmaceuticals Over Use of Contaminated IV Bags in Sterile Injectable Drug Production - geneonline.com
Amneal gets FDA nod for generic version of Risperdal Consta - MSN
Does Amneal Pharmaceuticals Inc. have pricing powerDollar Strength & Weekly Stock Breakout Alerts - خودرو بانک
Trexquant Investment LP Acquires 167,631 Shares of AMNEAL PHARMACEUTICALS, INC. $AMRX - MarketBeat
Should you avoid Amneal Pharmaceuticals Inc. stock right nowJuly 2025 Action & Low Risk Profit Maximizing Plans - خودرو بانک
Using R and stats models for Amneal Pharmaceuticals Inc. forecastingEarnings Risk Report & Advanced Technical Signal Analysis - Newser
What is the Moat Score of Amneal Pharmaceuticals Inc.2025 Biggest Moves & Reliable Entry Point Alerts - خودرو بانک
Why Amneal Pharmaceuticals Inc. is moving todayGap Down & Smart Money Movement Alerts - Newser
FDA approves Amneal’s generic risperidone for schizophrenia treatment By Investing.com - Investing.com Australia
Is Amneal Pharmaceuticals Inc. showing insider buyingCEO Change & Free Expert Verified Stock Movement Alerts - خودرو بانک
Tools to monitor Amneal Pharmaceuticals Inc. recovery probabilityShort Setup & AI Powered Market Trend Analysis - Newser
Published on: 2025-09-05 05:42:34 - Newser
Regression analysis insights on Amneal Pharmaceuticals Inc. performanceWeekly Market Report & Accurate Intraday Trading Signals - Newser
Hsbc Holdings PLC Has $727,000 Stake in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Can Amneal Pharmaceuticals Inc. rally from current levelsWeekly Trend Report & Intraday High Probability Setup Alerts - Newser
Can technical indicators confirm Amneal Pharmaceuticals Inc.’s reversalMarket Movement Recap & Expert Curated Trade Setup Alerts - Newser
Amneal Pharmaceuticals Receives FDA Approval for Antipsychotic Medicine - AInvest
Amneal receives U.S. FDA approval for risperidone extended-release injectable suspension - MarketScreener
FDA approves Amneal’s generic risperidone for schizophrenia treatment - Investing.com
Amneal Pharmaceuticals Receives FDA Approval for Risperidone Extended-Release Injectable Suspension - Quiver Quantitative
Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension - GlobeNewswire
Amneal Pharmaceuticals Receives FDA Approval for Risperidone Extended-Release Injectable Suspension, Expanding Complex Injectables Portfolio - AInvest
$194M Market Opportunity: Amneal Secures Exclusive FDA Approval for Complex Injectable Schizophrenia Drug - Stock Titan
Has Amneal Pharmaceuticals Inc. formed a bullish divergence2025 Trade Ideas & Consistent Growth Equity Picks - Newser
Detecting price anomalies in Amneal Pharmaceuticals Inc. with AIQuarterly Market Review & Fast Gain Stock Trading Tips - Newser
Will Amneal Pharmaceuticals Inc. continue its uptrendVolume Spike & Daily Volume Surge Signals - Newser
Can Amneal Pharmaceuticals Inc. expand into new marketsWeekly Investment Summary & Capital Protection Trading Alerts - خودرو بانک
Amneal Pharmaceuticals Inc (AMRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.67%
0.04%
자본화:
|
볼륨(24시간):